PCSK9s Get Boost From IMPROVE-IT; Outcomes Data Restores Faith In LDL Surrogate
This article was originally published in The Pink Sheet Daily
Executive Summary
Reduction in events with Merck’s Zetia as add-on therapy despite a modest LDL-lowering effect bodes well for Sanofi/Regeneron and Amgen’s PCSK9 inhibitors, which have large effects on LDL.